Paddington Life Sciences

Paddington

Life Sciences

Paddington Life Sciences is a thriving innovation ecosystem, bringing together the NHS, communities, researchers and industry for health innovation at scale.

Centred around the historic St Mary’s Hospital, Paddington Life Sciences is driven by founding industry partners with a shared commitment to generating healthcare innovation, alongside health, economic and social value in Paddington.

Paddington Life Sciences is driven by an influential partnership group with industry partners amongst its founding members. Partners have agreed to work together to improve health and reduce inequalities through four key areas of focus: social value, diversity & inclusion in clinical trials, data & digital and place & space.

To date, the Paddington Life Sciences Partners are: British Land, Brockton Everlast, Derwent London, Imperial College Healthcare NHS Trust, Imperial College London, IQVIA, Microsoft, Optum, Oracle Health, Takeda, The Paddington Partnership, Vertex and Vodafone.

1,000,000 patient contacts analysed per year though the NIHR Biomedical Research Centre.

The world’s first gene-editing treatment for blood disorders was approved in 2024, following a clinical trial led by Imperial College Healthcare.

Imperial College Healthcare NHS Trust has the most extensive integrated health data set in the UK and through Paddington Life Sciences, we aim to leverage the potential of our data assets.

Paddington Life Sciences is part of the Imperial WestTech Corridor.

Facilities & infrastructure

A dedicated digital collaboration space hosted by Imperial College Healthcare that provides secure access and analysis to one of the most extensive integrated health data sets in the UK.

The redevelopment of the hospital estate will an additional 5 million ft2 of cross-functional commercial and lab space for life science businesses.

The Fleming Centre is expected to open in 2028, and will combine cutting edge research, public engagement and work with policymakers to drive a global change against antimicrobial resistance. HRH Prince William is patron of the appeal to build the centre.

The proposed redevelopment of Waterside House in Paddington Basin will increase the site from 220,000 ft2 to 400,000 ft2 (STPP). Given the co-location with St Mary’s Hospital, there is an ambition to redevelop the use of the building to support the growing innovation ecosystem.

The NIHR Imperial Biomedical Research Centre (BRC) is a translational research partnership between Imperial College Healthcare NHS Trust and Imperial College London and is the largest BRC in the country.

In-Vitro Diagnostics Co-operative is one of the four centres in England that generates evidence to support diagnostic test development.

Additional information

Paddington Life Sciences is working with the Westminster City Council to halve the 18-year gap in life expectancy between those with the highest and lowest life expectancy by 2035.

Through social value programmes, Paddington Life Sciences is supporting local communities and tackling inequalities through community engagement, with a focus on increasing access to education and employment and improving digital inclusion.

Working with the Partners, Paddington Life Sciences is committed to addressing the wider determinants of health as a part of the clusters Social Value work. Importantly this links into work Westminster City Council is leading through #2035, their North Paddington programme and their ‘Westminster Anchors Alliance’.

Paddington Life Sciences has chosen to focus on two areas which communities have informed are critical gaps and align with the cluster’s areas of expertise and resources:

  • Education, skills and employment
  • Digital inclusion

In 2023/24, Imperial College Healthcare NHS Trust supported more than 1,000 research studies and recruited 18,000 participants.

MORE PLACES

Categories:

[email protected]
+44 (0)20 3179 8100

© 2024 MedCity All Rights Reserved
Site by XYCO